Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease Hypoglycemic Regimen Study
ChiCTR2000037559Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of metformin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (5 arms), sponsored by Changhai Hospital. Primary endpoint: liver fat content. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2000037559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037559.